The STAT First Opinion discussion with PharmedOut's Bencivenga and Fugh-Berman correctly flags the post-2023 surge in perimenopause framing as a social-media phenomenon that pathologizes normal midlife transitions, yet it underplays how this narrative directly conflicts with longitudinal data showing vasomotor symptoms affect only 40-60% of women and often resolve without intervention. An observational cohort study in JAMA Internal Medicine (n=3,302, 10-year follow-up) found irregular cycles common but not predictive of severe impairment when adjusted for sleep and stress confounders, contrasting sharply with influencer claims of inevitable 'ruin.' No RCTs support routine hormone initiation in the perimenopausal window; the Women's Health Initiative reanalysis (observational arm, n>27,000) revealed elevated breast-cancer and cardiovascular signals persisting years post-use, with industry funding ties noted in 38% of positive supplement trials per a 2022 Cochrane systematic review. This pattern repeats historical medicalization of female physiology, now accelerated by unvetted supplement marketing that bypasses FDA oversight and exploits rising distrust in conventional care. Few outlets connect the dots to parallel misinformation waves around thyroid and adrenal fatigue, where similar symptom clusters drive over-testing and polypharmacy without improving outcomes in controlled studies.